Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A Bayesian adaptive biomarker stratified phase II randomized clinical trial design for radiotherapies with competing risk survival outcomes

Statistical Methods in Medical Research(2023)10.1177/09622802231215801Source: DataRank Database

A Bayesian adaptive biomarker stratified phase II randomized clinical trial design for radiotherapies with competing risk survival outcomes is a research paper published in Statistical Methods in Medical Research (2023). On theSindex it has a DataRank of 0. It has been cited 2 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access2 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 0.50)OA: greenTopics (42)Linked Datasets (2)DataCite Reuse (2)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Wenjing Hu ORCID,Ick Hoon Jin ORCID,Hao Liu ORCID,Yong Zang ORCID,Jina Park ORCID

Live enrichment

PubMed:38062757 PMC:PMC11227940 OpenAlex:https://openalex.org/W4389486074

NIH

Grant: P30 CA082709

NIH

Grant: R01 GM150808

NIH

Grant: R21 CA264257

Ralph W. and Grace M. Showalter Research Trust Fund

FWCI

0.50

Citation Percentile

0.7%

Citation Trend

2025

2026

greenLicense: https://journals.sagepub.com/page/policies/text-and-data-mining-license

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11227940/pdf/nihms-2004169.pdf

publisherhttps://journals.sagepub.com/doi/pdf/10.1177/09622802231215801

publisherhttps://journals.sagepub.com/doi/full-xml/10.1177/09622802231215801

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/11227940

Fields of Study

Statistical Methods in Clinical TrialsOptimal Experimental Design MethodsCancer Genomics and DiagnosticsHumansBayes TheoremBiomarkersResearch DesignRandomized Controlled Trials as TopicClinical Trials, Phase II as Topic

MeSH Terms

Bayes TheoremClinical Trials as TopicHumansRandom AllocationResearch DesignBiomarkersRandomized Controlled Trials as TopicClinical Trials, Phase II as Topic

Keywords

MedicineRandomized controlled trialBayesian probabilityHazard ratioSubgroup analysisRadiation therapyClinical trialRandomizationOncologyBiomarkerClinical endpointClinical study designInternal medicineMedical physicsComputer scienceMeta-analysisConfidence intervalArtificial intelligenceBiologyRadiotherapyUtility FunctionPhase Ii Clinical TrialCompeting Risk ModelBayesian Adaptive RandomizationBiomarker Stratified Design

Sustainable Development Goals

SDG 0: Good health and well-being

sj-pdf-1-smm-10.1177_09622802231215801 - Supplemental material for A Bayesian adaptive biomarker stratified phase II randomized clinical trial design for radiotherapies with competing risk survival outcomes

10.25384/sage.24778587SAGE Journals

10.25384/sage.24778587.v1SAGE Journals